ICRA maintains stable outlook for Indian pharma companies
Domestic pharma cos expected to grow at a CAGR of around 10-12% between FY2019-2022. The productivity of R&D expenditure, operational risk related to an increased level of due diligence by regulatory agencies and price controls are key concerns